Related News
Sanofi sets up Asia Pacific R&D center in Shanghai
FRENCH pharmaceutical company Sanofi said it has unveiled its Asia Pacific research and development hub in Shanghai as it strengthens local R&D capabilities to fuel growth.
As the first one in the region and the fifth for Sanofi worldwide, the Asia Pacific R&D hub will integrate its existing R&D capabilities in biopharmaceuticals, animal health, rare diseases and vaccines, the company said. The facility will bring together R&D centers in 12 countries in Asia Pacific with about 1,400 staff.
It also announced partnership with the GPCR Institute, a network of research centers focusing on biopharmaceutical research, as well as a licensing agreement with local biotech company Zai Lab, in an effort to drive collaboration with the local talents.
“The launch of the Asia Pacific R&D hub marks our efforts to transform R&D results and ensure sustainable growth in the coming years,” said Elias Zerhouni, president of Sanofi’s global R&D.
Sanofi intends to bring all projects in its global R&D pipeline to the region as soon as possible and to further strengthen its scientific network at both home and abroad.
The company now has more than 50 collaborative projects with partners in the Asia Pacific region and it plans to accelerate the introduction of innovative drugs into the China market.
“Asia Pacific is home to a wide spectrum of healthcare needs and we are excited to enhance our ability to capture opportunities and to respond to changing market demands,” said Frank Jiang, vice president and head of the Asia-Pacific R&D Hub at Sanofi.
Sanofi first set up its R&D unit in China in 2005 and gradually expanded its presence over the years.
- About Us
- |
- Terms of Use
- |
-
RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证:沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证:31120180004
- |
- 网络视听许可证:0909346
- |
- 广播电视节目制作许可证:沪字第354号
- |
- 增值电信业务经营许可证:沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.